Haimei Xing

Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase

Yunhang Guo, Ye Liu, Nan Hu et al. · Journal of Medicinal Chemistry · 2019 · 349 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16

Sonrotoclax overcomes BCL2 G101V mutation–induced venetoclax resistance in preclinical models of hematologic malignancy

Jiuyang Liu, Shuran Li, Qin Wang et al. · Blood · 2024 · 71 citations · Full text

Medicine, Oncology, Pharmacology +15

BTK Leu528Trp - a Potential Secondary Resistance Mechanism Specific for Patients with Chronic Lymphocytic Leukemia Treated with the Next Generation BTK Inhibitor Zanubrutinib

Sasanka M. Handunnetti, Chloe Pek Sang Tang, Tamia Nguyen et al. · Blood · 2019 · 67 citations

Medicine, Oncology, Pharmacology +9

Construction of a versatile expression library for all human single-pass transmembrane proteins for receptor pairings by high throughput screening

Wei Yang, Søren Berg Padkjær, Jishu Wang et al. · Journal of Biotechnology · 2017 · 38 citations

Life Sciences, Biochemistry, Molecular Biology +16

BTK kinase activity is dispensable for the survival of diffuse large B-cell lymphoma

Hongwei Yuan, Yutong Zhu, Y. Cheng et al. · Journal of Biological Chemistry · 2022 · 25 citations · Full text

Medicine, Molecular Biology, Oncology +17